- Shuffle
Toggle OnToggle Off
- Alphabetize
Toggle OnToggle Off
- Front First
Toggle OnToggle Off
- Both Sides
Toggle OnToggle Off
Front
How to study your flashcards.
Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key
Up/Down arrow keys: Flip the card between the front and back.down keyup key
H key: Show hint (3rd side).h key
![]()
PLAY BUTTON
![]()
PLAY BUTTON
![]()
267 Cards in this Set
- Front
- Back
|
Glasgow Coma Scale
|
assess LOC, verbal and motor ability; scale 3-15; higher the better, <8 = coma
|
|
Intracranial space components
|
brain tissue, blood, CSF
|
|
NORM ICP
|
5-15 mmHg
|
|
Causes for transient increase in ICP
|
sneezing, straining, defecation, coughing, blowing nose
|
|
Early sign of IICP
|
vision; diplopia, blurred, lower acuity
|
|
Later signs of IICP
|
personality change, thought process change, h/a, N
|
|
Cause of IICP
|
compliance and accommodation fails with increasing volume in intracranial space
|
|
Cascade of IICP effects
|
IICP-> dec. cerebral perfusion -> tissue hypoxia, lower pH, inc. CO2
|
|
Tests for IICP
|
CT(cause), MRI
|
|
Medical management of IICP
|
craniotomy, craniectomy, tumor removal, drain ventricles, drain hematoma, intubation
|
|
Medication management of IICP
|
osmotic diuretics, loop diuretics, corticosteroids, antipyretics, anticonvulsants, histamine antagonists, barbiturates
|
|
COA of osmotic diuretics for Tx of IICP
|
lowers ICP by inc. blood osmolality, draws blood from edemitus brain tissue into vascular circulation
|
|
COA of antipyretics for Tx of IICP
|
controls hyperthermia (which increases metabolic rate in brain)
|
|
COA of histamine antagonists for Tx of IICP
|
lowers risk of stress ulcers
|
|
COA of barbiturates for Tx of IICP
|
barbiturate-induced coma; lowers metabolic demand of tissue
|
|
Nursing interventions to improve cerebral perfusion
|
elevate HOB 30 degrees, avoid valsalva's, quiet environment (lower stress), cluster activity (provide rest periods), restrict fluids, avoid freq. suctioning, O2, hypothermia blanket
|
|
Define seizure
|
excessive and abnormal transient electrical activity within the brain usually resulting in involuntary body movements
|
|
Causes of seizures
|
idiopathic, hypoglycemic, electrolyte imbalance (hyperkalemia), trauma, infection, IICP, toxins
|
|
1/2 of all seizures
|
idiopathic
|
|
Partial seizures
|
do not always involve loss of conciousness, may develop into generalized seizures
|
|
Simple partial seizure
|
1 hemisphere, uncontrolled movement, Pt has memory of incident and can interact during seizure
|
|
Complex partial seizure (psychomotor)
|
inappropriate behaviors, effects LOC, often includes feeling an "aura" prior, common to have amnesia about event
|
|
Generalized seizure
|
usually affects LOC
|
|
Absence seizure
|
type of generalized seizure; 5-30 sec., can have >100/day, no movement, unresponsive, "daydreaming", can be commonly found in kids
|
|
Tonic-clonic seizure
|
type of generalized seizure; periods of rhythmic jerking and relaxation
|
|
"tonic" period
|
15-60 sec.; may see cyanosis, cease to breath, urinary/bowel incontinence
|
|
"clonic" period
|
60-90 sec.; jerking, eyes roll back in head, hyperventilation
|
|
postictal phase of tonic-clonic seizure
|
quiet, relaxed, no movement, not concious, eventually wakes confused
|
|
Atonic seizure
|
type of generalized seizure; sudden loss of tone in muscle, collapse/fall or dropping object, may have brief loss of conciousness, no postictal phase
|
|
Status epilepticus
|
emergency; prolonged seizure or several seizures right after eachother lasting >30min.
|
|
List anticonvulsants/seizure medications
|
dilantin, valium, depakene, neurontin, tegrital
|
|
Seizure precautions
|
low bed position, padded side rails, side rails up, IV access, O2 and suction equipment ready
|
|
Precautions during seizure
|
lower Pt to floor, pillow under head, do not restrain, no tongue blade, prevent aspiration by turning on side, loosen clothing around neck, document
|
|
Describe MS
|
AI disease effecting the myelin sheath, causing slow/loss of nerve conduction expressed through exacerbations/remissions
|
|
Subjective MS s/s
|
wide range depending on loc. or myelin damage- shaking, weakness, numb, tinnitus, visual s/s, difficult chewing and walking, incontinent, impotent
|
|
Objective MS s/s
|
ataxia, behavior change, nystagmus, spasticity, tremors, dysphagia, palsy, impaired speech, incontinence, impaired judgement
|
|
Dx tools for MS
|
CSF (inc. protein, WBC, and IgG), MRI (plaques), CT (plaques), visual/auditory/brainstem evoked potential, electromyography
|
|
MS meds (types)
|
corticosteroids, muscle relaxers, immunosupressants, immunomodulators
|
|
Corticosteroids- action
|
reduce edema and inflammatory response during exacerbations
|
|
Corticosteroids- types
|
ACTH, Solu Medrol, Prednisone
|
|
Muscle Relaxers- action
|
reduces muscle spasticity
|
|
Muscle Relaxants- types
|
Baclofen, Dantrolene, Valium
|
|
Immunosuppressants- action
|
stability disease (MS) process
|
|
Immunosuppressants- types
|
Imuran, Cytoxan
|
|
Immunomodulators- action
|
slows disease (MS) progression
|
|
Immunomodulators- types
|
Avonex, Betaseron, Copaxone
|
|
MS Nursing Interventions
|
inc. energy in morning, rest/relaxation periods, maintain constant temp., set priorities, pace activities, adaptive devices
|
|
describe Parkinson's
|
a chronic degenerative disease of neurons of the basal ganglia, causing a deficiency in dopamine
|
|
1st s/s of Parkinson's
|
fatigue, problems w/dexterity, minor tremors
|
|
Other s/s Parkinson's
|
muscle rigidity, "pill rolling", uncoordination, stooped posture, shuffling gait, mask-like face, dysphagia, drooling, monotone, dementia, akinesia/bradykinesia
|
|
Dx Parkinson's
|
no test; based on symptoms and response to med
|
|
Parkinson's Meds (types)
|
dopaminergics, dopamine agonists, monoamine oxidase inhibitors, anticholinergics
|
|
Dopaminergics- action
|
inc. mobility by red. tremors and rigidity, increases dopamine release
|
|
Dopaminergics- types
|
levodopa, sinemet, symmetrel
|
|
Dopamine agonists- action
|
activates dopamine receptors (used in conj. w/dopaminergics)
|
|
Dopamine agonists- types
|
parlodel, permax, mirapex, requip
|
|
MAOI- action
|
used early in Parkinson's, blocks dopamine metabolism
|
|
MAOI- types
|
eldepryl
|
|
Anticholinergics- action
|
eases drooling, tremors, rigidity
|
|
Anticholinergics- types
|
artane, cogentin, parsidol, akineton
|
|
Parkinson's Nursing Interventions
|
ROM, ambulate 4xday, assistive devices, speech pathologist, OT, food consistencies, sleep-wake cycle, strategies to promote sleep
|
|
Describe Myasthenia Gravis
|
AI disease affecting ACh receptors at the neuromuscular junction
|
|
Early s/s of MG
|
ptosis, diplopia
|
|
Other s/s of MG
|
weakness, dysarthria, dysphagia, difficulty sitting, resp. distress
|
|
Dx MG
|
+ tensilon test, EMG, ACh receptor Ab serum levels
|
|
MG medications- types
|
Anticholinesterases, immunosuppressives, procedures
|
|
Anticholinesterases- action
|
allows ACh to collect @ neuromuscular junction @ ACh receptor sites; promotes muscle contraction
|
|
Anticholinesterases- types
|
mestinon, prostigmin, mytelase
|
|
Immunosuppressives- action
|
improves strength, reduces inflammation
|
|
Immunosuppressives- types
|
prednisone, imuran (lowers ACh Ab in months)
|
|
Procedures to treat MG
|
plasmaphoresis, thymectomy (40% remmission w/ Pt<40 y/o)
|
|
MG Nursing Interventions
|
assist w/turning, coughing, incentive spir., semi-fowler's, hydrate (<2500), food consistencies, meal/med sched., small bites, know heimlich
|
|
Myasthenic crisis
|
caused by low ACh, stress, or infection, exacerbation of MG s/s, respiratory arrest
|
|
Cholinergic crisis
|
toxic rxn to percription, too much ACh, causing sudden extreme weakness, respiratory arrest
|
|
Distinguishing factor b/t myasthenic and cholinergic crisises
|
Myasthenic crisis = + tensilon test
|
|
Amyotrophic lateral sclerosis
|
lou gehrig's disease; chronic, rapidly progressing degenerative disease of motor neurons, causing eventual paralysis of resp. muscles
|
|
early ALS s/s
|
weakness, fasciculations, uncoordinated, spasticity, paresis, hyperreflexia, atrophy
|
|
other ALS s/s
|
dysarthria, dyspnea, difficulty coughing and chewing, dysphagia, emotional, loss of control
|
|
ALS prognosis
|
50% die in 2-5 yrs following Dx due to resp. failure or aspiration pn.
|
|
Dx of ALS
|
EMG, muscle biopsy, mostly process of elimination
|
|
ALS nursing interventions
|
ROM q2hr, + N balance, hydrate, monitor infection, assist turning, coughing, incentive spir., turn q2hr, elevate HOB >30, suction, oxygen
|
|
Describe Huntington's disease
|
genetically dominant inherited degenerative disease of the nervous system; ex. woody guthrie
|
|
early Huntington's motor s/s
|
restless, fidgety, gait and posture changes, protruding tongue, slurred speech
|
|
late Huntington's motor s/s
|
chorea, grimacing, dysphagia, unintelligible speech, impaired diaphragmatic movement, resp. problems
|
|
early Huntington's psychosocial s/s
|
irritability, outbursts, dperession, risk for suicide
|
|
late Huntington's psychosocial s/s
|
decreased memory, loss of cognition, dementia, total dependence
|
|
Dx of Huntington's
|
genetic tests
|
|
Huntington's meds
|
antipsychotics (block dopamine rec.) and antidepressants
|
|
Huntington's nursing interventions
|
upright positioning, heimlich, thickened food consistency, calm env., continue feeding when turns head away, high cal snacks/food, avoid milk, adaptive tools, oral hygeine, alternative/therapeutic communication
|
|
Describe Alzheimer's
|
progressive, degenerative form of dementia causing a deterioration of general intellect
|
|
1st stage Alzheimer's
|
still alert, memory lapses, subtle personality changes, dec. attention span, restless, forgetful, congitive deficits
|
|
2nd stage Alzheimer's
|
more memory problems, disoriented to time/place, language deficits (paraphasia, eccolalia, scanning speech), sensorimotor deficits (apraxia, astereognosis, agraphia), wandering, periods of lucidity
|
|
apraxia
|
unable to do purposeful movements or use objects properly
|
|
astereognosis
|
inability to identify objects by touch
|
|
agraphia
|
inability to write
|
|
paraphasia
|
using the wrong word
|
|
eccolalia
|
repition of same words/phrases
|
|
scanning speech
|
searching for the words
|
|
3rd stage Alzheimer's
|
total disorientation, inability to communicate, incontinent, loss of cognition
|
|
stage 3 Alzheimer's complications/risks
|
pneumonia, dehydration, falls, paranoia
|
|
Dx Alzheimer's
|
no test; EEG pattern, MRI/CT (hippocampus shrink), PET, folstein's mini-mental status exam, fam Hx, autopsy
|
|
Alzheimer's prognosis
|
7 yrs from Dx
|
|
Alzheimer's meds- types
|
cholinesterase inhibitors, tranquilizers, supplements, complementary therapies
|
|
cholinesterase inhibitors- types
|
for mild-mod dementia; cognex, aricept, exelon
|
|
tranquilizers- types
|
for aggitation; mellaril, haldol
|
|
Alzheimer's supplements
|
vit c & e, folic acid, vitamin B12
|
|
Alzheimer's complementary therapies
|
massage, herbs (gingko), coenzyme Q10, art/music/dance therapy
|
|
Alzheimer's Nursing interventions
|
calenders, lists, alarms, med boxes, safety in kitchen, program emergency phone #s, life-line, labels, remove toxins/hazards, min. stimuli, ID self every time and orient, repeat, boundaries, continuity [caregiver role strain]
|
|
describe Guillain-Barre
|
AI disorder causing muscle weakness and paralysis
|
|
GB s/s
|
flaccid paresthesias, symmetric LE weakness, progressive weakness to UE and face, possible resp. arrest
|
|
Dx GB
|
physical exam, Hx, CSF (inc. protein, norm cell count), EMG studies
|
|
GB meds
|
analgesics, antibiotics, anticoagulents, vasopressors (if HTN)
|
|
Procedure r/t GB
|
tracheostomy, plasmaphoresis
|
|
describe TIA
|
brief attack of localized cerebral ischemia lasting <24 hrs, considered a warning sign for CVA
|
|
cause for CVA
|
dec. blood flow to brain by ischemia or hemorrhage
|
|
CVA motor s/s
|
opposite side effects, balance, coordination, gait, proprioception
|
|
CVA sensory s/s
|
aphasia, agnosia, apraxia, neglect syndrome, visual difficulty
|
|
CVA cognitive s/s
|
denial, impaired memory/judgement, unable to concentrate, disoriented, slow and cautious, depressed and anxious, angers quickly
|
|
CVA Dx
|
CT w/o contrast, MRI, cerebral angiogram
|
|
CVA meds
|
thrombolytics (w/in 3 hrs), antiplatelets/anticoagulants (contraindicated for hemorrhagic), corticosteroids, anticonvulsants, carotid endarterectomy, aneurysm repair
|
|
Races at greater risk for DM
|
AA, NA, hispanic/LA
|
|
DM complications
|
leading cause of heart disease, stroke, adult blindness, end stage renal failure, non-traumatic LE amputation
|
|
glucagon
|
produced by alpha cells in pancreas, stimulates glycogenolysis, increasing BG levels
|
|
somatostatin
|
produced by delta cells of pancreas, inhibits glucagon and insulin secretion, maintaining current BG levels
|
|
Type 1 DM
|
AI disease where beta cells are destroyed, absolute insulin deficient; 5-10% of cases, usually <25 y/o, "juvenile onset" or "insulin dep."
|
|
Type 2 DM
|
no beta cell destruction, insufficient insulin prod. or cell resistence to insulin; 90% of cases, usually >40 y/o, "adult onset" or "non- insulin dependent"
|
|
Gestational D
|
transitory glucose intolerance; 2-5% of pregnancies
|
|
Etiology of Type 1 DM
|
genetic predisposition + environmental trigger, AI, more common in the young and men
|
|
s/s of Type 1 DM
|
polyuria, polydipsia, polyphagia, glycosuria, weight loss, malaise, fatigue, blurred vision
|
|
Etiology of Type 2 DM
|
genetic predisposition, advancing age, obesity, inactivity, race/ethnicity, more common in women than men, pregnancy, baby >9lbs, polycystic ovary syndrome
|
|
s/s of Type 2 DM
|
usually asymptomatic, hyperglycemia, polyuria, polydipsia, blurred vision, fatigue, paresthesias, prolonged healing, recurrent skin/vaginal infection
|
|
Casual plasma DM Dx test
|
casual BG taken any time of day w/out regard to last meal, activity, etc.; >200
|
|
Fasting plasma DM Dx test
|
fasting (>8 hr) glucose level >126
|
|
Glucose tolerance test for DM Dx
|
glucose bolus of 75 g, in 2 hrs, BG>200
|
|
Requirement to Dx DM
|
positive one of 3 tests + a positive result of different test on different day
|
|
Glycoslylated hemoglobin test ranges
|
<7%= good control, 7-9%= fair control, >9%=poor control
|
|
glycosylated hemoglobin test action
|
glucose permanently attaches to Hgb, the more glucose in blood, the more glycosylated Hgb, not effected by meals, time of day, drugs, stress, activity; shows diabetic control for last 100 days
|
|
urine glucose test
|
when renal glucose threshold exceeded; 180-200 BG level
|
|
urine ketone test
|
when fatty acids are being metabolized for energy
|
|
microalbumin test
|
indicates pending ketoacidosis
|
|
need to take a diabetes monitoring test when...
|
diabetic is ill, stressed, any s/s, or BG level >300
|
|
5 componenets of diabetes management
|
diet, exercise, medications, self-monitoring of BG, and education
|
|
diabetic diet; cals from carbs
|
60-70%
|
|
diabetic diet; cals from protein
|
15-20%
|
|
diabetic diet; cals from fat
|
<10%
|
|
diabetic diet; fiber
|
20-35 g/day
|
|
diabetic diet; sodium
|
1000-3000 mg/day MAX
|
|
diabetic diet; alcohol
|
men: <2 drinks/day
women: <1 drink/day alcohol potentiates the hypoglycemic effect of insulin or other diabetic meds |
|
effects of exercise on diabetes
|
lowers BG levels by inc. uptake of glucose in muscles, dec. risk for insulin resistance, reduces CV risks, improves muscle tone and circulation, dec. total cholesterol and triglycerides, assists in weight loss
|
|
Type 1 DM exercise rec.
|
20-40 min.; 4-7 days/wk
|
|
Type 2 DM exercise rec.
|
30 min. aerobic; 3 days/week
|
|
Exercise limitations for DM
|
no exercise if ketones found in urine; no prolonged exercise; if long period of activity, check BG before, during and after; no exercise w/in 1 hr of insulin or peak insulin action; eat 15g carb snack before; add additional 15-30 g carb snack for every additional 30-60 min.
|
|
methods of insulin admin.
|
subcu, IV
|
|
subcutaneous insulin
|
fastest absorption in abdomen, then thigh & butt; on regular schedule, sliding scale, or continuous infusion
|
|
IV insulin
|
IV push or continuous drip
|
|
oral hypoglycemics- types
|
sulfonylureas, biguanides, meglitinides, alpha-glucosidase inhibitors, TZDs
|
|
sulfonylureas- types
|
glyperide, glypizide, dolputamide
|
|
sulfonylureas- action
|
stimulates pancreas to release more insulin AND increases sensitivity of tissue to insulin (non-obese T2)
|
|
biguanides- type
|
metformin
|
|
biguanides- action
|
prevents liver from releasing more glucose AND increasing muscle cell insulin sensitivity
|
|
meglitinide- type
|
starlex
|
|
meglitinides- action
|
stimulates pancreatic cells to release more insulin
|
|
alpha-glucosidase inhibitors- action
|
slows intestinal digestion allowing increased time for carbohydrate absorption
|
|
TZDs- types
|
avandia and actos
|
|
TZDs- action
|
increased muscle cell insulin sensitivity
|
|
DM Client education topics
|
normal met., diabetes & met., diet, exercise, s/s of hyper-/hypo- glycemia, self administering, self-monitoring, foot care, sick days, community
|
|
Diabetic foot problems; source
|
abnormal pressure distribution or trauma s/t neuropathy, vascular disease w/diminished blood flow
|
|
Diabetic foot care
|
wash and inspect daily, file nails w/round corners, never go barefoot, test water temp w/hand, wear leather shoes w/cotton socks
|
|
Diabetic sick day goals
|
prevent dehydration, provide nutrition for recovery
|
|
Diabetic sick day management
|
monitor BG q3 or q4hr, continue insulin/meds, sip 8-12 oz. glucose fluid every hr., soft foods, rest- no exercise
|
|
Diabetic sick day; call MD if...
|
s/s of infection, illness >2 days, unable to eat >24 hr, vomiting/diarrhea >6 hrs, BG >400 two tests, urine + for glucose, ketones in urine >200
|
|
Increased risks for Diabetic surgery Pt
|
postop infection, delayed wound healing, fluid/electrolyte imbalance, hypoglycemia, DKA
|
|
Diabetic surgery
|
best met. state, regular insulin given w/IV glucose solution, 1/2 dose short-acting insulin preop, 1/2 dose PACU, oral hypoglycemics held 1-2 days preop, T2 may need perioperative insulin, early morning surgery, if NPO postop IV dextrose admin. on sliding scale
|
|
DM complications
|
hyper-/hypo-glycemia, dawn phenom., somogyi phenom., DKA, HHNK
|
|
describe hypoglycemia
|
BG<70; caused by mismatch of insulin or oral hypoglycemic, too much exercise, too little food
|
|
Mild hypoglycemia
|
40-60 BGL; sweating, tremor, tachycardia, palpitations, nervousness, hunger
|
|
Moderate hypoglycemia
|
20-40 BGL; h/a, lightheaded, double vision, drowsy, confused, numb lips/tongue, slurred speech
|
|
Severe hypoglycemia
|
BGL<20; disoriented, difficulty arousing from sleep, loss of consciousness, seizure
|
|
treatment of mild hypoglycemia
|
15 g CHO; 8 oz. milk, 4 oz. juice/soda, 5 hard candy, 3 marshmallows, 2-3 tsp sugar, 3-4 dextrose tabs; recheck 15 min., another snack if s/s persist
|
|
treat severe hypoglycemia
|
conscious; 15 g CHO fast-acting, simple; then d50% 10ml/min IV followed by D5W 10 g/hr
unconscious; glucagon 0.5-1 mg IM or subcu |
|
describe hyperglycemia
|
BGL>200; caused by too little insulin or oral hypoglycemics, too much food, too little exercise, illness/stress
|
|
s/s of hyperglycemia
|
extreme thirst, hunger, freq. urination, blurred vision, drowsiness, nausea
|
|
describe Somogyi effect
|
fasting hyperglycemia; normal or high BGL @ bedtime, decreased BGL @ 2-3 am, followed by hyperglycemia caused by counter-reg. hormones
|
|
treatment of somogyi effect
|
decrease evening dose of insulin or increase bedtime snack
|
|
describe the Dawn phenomenon
|
fasting hyperglycemia; norm BGL, rise in BGL @ 3-4am, then glucose levels rise along w/ GH; differentiated from somogyi by taking BGL @ 3 (SE=hypo, DP=norm)
|
|
treatment of Dawn phenomenon
|
change time of evening insulin from dinnertime to bedtime
|
|
describe DKA
|
severe insulin deficiency in T1 DM clients; develops over several hrs/days
|
|
stages of DKA
|
1. hyperglycemia, 2. dehydration, 3. acidosis
|
|
DKA s/s
|
altered consciousness, kussmaul's resp., fruity breath, N/V, increased urine prod.
|
|
Lab findings for DKA
|
BSL = 300-800, inc. plasma ketones, urine ketones & glucose, ABGs= met. acidosis
|
|
treatment of DKA
|
fluid therapy, insulin drip, monitor/admin. electrolytes, EKG, hourly BG checks, assess vs, lungs, I/O, ketones
|
|
describe HHNK
|
slow onset of extreme hyperglycemia w/o ketosis/acidosis, found in T2 DM clients
|
|
s/s of HHNK
|
BSL= 600-2000, hypotension, tachycardia, extreme thirst; all r/t profound dehydration; altered LOC, neuro deficits, seizure, dry skin/mucous membranes
|
|
HHNK risks
|
stress, INFECTION, trauma, surgery, dehydration, TPN, drugs (thiazides, glucocorticoids, phenytoin)
|
|
chronic DM complications
|
atherosclerosis, PVD, inc. risk for CAD, CVD, PVD, retinopathy, nephropathy, neuropathy
|
|
prevalence of diabetic retinopathy
|
after 20 yrs of DM, almost all T1 DM, and 60% T2 DM
|
|
describe diabetic retinopathy
|
chronic progressive non-inflammatory impairment of retinal circulation, eventually causing hemorrhage, causing perm. vision changes to blindness
|
|
treatment for diabetic retinopathy
|
control HTN & BSL, photocoagulation, vitrectomy, cataract removal/lens implant
|
|
prevalence of diabetic nephropathy
|
20-40% DM Pts; leading cause of morbidity and mortality in DM
|
|
1st sign of nephropathy
|
microalbuminuria
|
|
other s/s nephropathy
|
thirst, fatigue, anemia, weight loss, freq. UTIs
|
|
treatment for diabetic nephropathy
|
control HTN & BSL, monitor vs, I/O, BUN, creatinine, restrict protein, Na, K, dialysis, kidney transplant
|
|
peripheral neuropathy- types
|
polyneuropathy, mononeuropathy
|
|
describe polyneuropathy
|
bilateral sensory disorder; most common; begins in foot/toes
|
|
describe mononeuropathy
|
effects a single nerve, unilateral
|
|
visceral/autonomic neuropathy
|
involves the ANS (GI, sexual performance, sweating, etc.)
|
|
s/s of polyneuropathy
|
distal parasthesias, pain, aching, burning, feelings of cold, altered/impaired sensation
|
|
s/s neuropathy
|
absent reflexes, pain in LE, poor peripheral pulses, N/V, diarrhea, incontinence, skin breakdown, skin infection, parasthesias
|
|
treatment of neuropathy
|
control HTN & BSL, foot care, pain meds, bladder training program
|
|
Norm BP range
|
systolic <120
diastolic <80 |
|
prehypertensive BP range
|
systolic 120-139 OR
diastolic 80-89 |
|
stage 1 HTN ranges
|
systolic 140-159 OR
diastolic 90-99 |
|
stage 2 HTN ranges
|
systolic >160 OR
diastolic >100 |
|
risks for essential HTN
|
aging, fam Hx, African American or Native American, obesity, smoking, stress
|
|
etiology for 2ndary HTN
|
renal disorder, cardiovascular disorders, endocrine disorders (cushings), neurogenic disorders (tumor), meds (glucocorticoids, estrogen)
|
|
s/s of HTN
|
asymptomatic, h/a, edema, pattern of consistently high BP
|
|
Dx of HTN
|
UA, BUN, creatinine, electrolytes, glucose, corticoids, ketosteroids, cholesterol, triglycerides, CXR, EKG
|
|
Tx of HTN
|
DASH diet, Na restriction, weight reduction, moderate alcohol intake, exercise, relaxation tech., avoid caffeine/smoking
|
|
Drugs types for HTN
|
diuretics, b-blockers, Ca channel blockers, ACE inhibitors, Angio II antagonists, aldosterone receptor antagonists
|
|
HTN crisis
|
>240/120; uncontrolled HTN, requires immediate reduction in BP, life-threatening; quick organ damage to kidneys, heart, and vasculature
|
|
s/s of HTN crisis
|
systolic >240, diastolic >120, h/a, drowsy, confused, tachycardia, tachypnea, cyanosis, numbness, tingling, seizure, motor impairment
|
|
HTN crisis nursing actions
|
semi-Fowler's, admin. O2, IV vasodilators (nitroprusside, nicardipine, labetalol), monitor BP q5-q15min until diastolic 75-90, then q30min, neuro assessments
|
|
acute PVD
|
caused by arterial thromobosis or embolism, abrupt onset, usually in younger adults
|
|
chronic PVD
|
peripheral atherosclerosis, insidious, usually older adults
|
|
thrombosis production
|
inc. coagulation, clot on vessel wall, infection/inflammation, pooling of blood
|
|
embolism production
|
colt floats through circulation, usually originating in the heart and lodged in smaller vessel
|
|
s/s arterial embolism/thrombus
|
sudden or insidious pain (distal to obstruction), numbness in extremity, pallor/mottling of extremity, cool/cold skin, pulselessness, paralysis, line of demarcation
|
|
Dx of arterial occlusion
|
arteriography (gold standard)
|
|
arterial occlusion management
|
meds: anticoagulants, thrombolytics; surgery: thrombectomy, emolectomy, thromboendarterectomy
|
|
arterial occlusion nursing actions
|
IV fluids, no hot/cold on extremities, bed cradle, extremity on same plane or lower than heart, no knee raising in bed, no 90-degree hip flexion, monitor pulses, color, pain, temp.
|
|
PAD
|
caused by atherosclerosis in ab. and iliac aorta, femoral or popliteal arteries or distal arteries, usually men in 60s, 70s, or 80s
|
|
s/s PAD
|
intermittent claudication, pain w/rest (burning), parasthesias, diminished peripheral pulses, pallor w/elevation, rubor w/dependency, thin, shiny hairless skin, thickened toenails, skin discoloration or breakdown
|
|
complications of PAD
|
gangrene, amputation, rupture of AAA, infection, sepsis
|
|
Dx PAD
|
doppler, transcutaneous oximetry, angiography
|
|
nursing actions for PAD
|
no smoking, limit caffeine, foot cradle, socks, slippers, position changes, avoid leg crossing and restrictive clothing, adapt exercise, pain meds, pain relief tech., keep feet warm and dependent position, inspect feet daily, foot care
|
|
PAD procedures
|
peripheral angioplasty, athrectomy, bypass grafting
|
|
bypass grafting nursing actions
|
assess 6 p's of ischemia, no hip/knee bends, 24 hr bedrest, hydrate/IV fluids
|
|
PAD meds
|
aspirin, plavix, ticlid, trental, pletal
|
|
Buerger's disease
|
thrombangitis obliterans; inflammation of medium and small arteries and veins of hands and feet
|
|
common Buerger's Pt
|
young, male smokers 20-40 y/o
|
|
s/s of Buerger's
|
intermittent claudication in arch of foot, sensitivity to cold, numbness, diminished pulses, red/cyanotic extremities when dependent, ulcerations
|
|
management of Buerger's
|
stop smoking, prevent vasoconstriction, improve peripheral pulses, prevent complications
|
|
Raynaud's disease
|
vasospasms of small arteries of UE or LE, mostly in hands; white-blue-red
|
|
s/s Raynaud's
|
numbness, tingling, stiffness, decreased sensation, aching, pallor then cyanosis then rubor
|
|
management of Raynaud's
|
avoid triggers (cold), wear warm clothing, avoid injuries to fingers/hands, Ca channel blockers, muscle relaxants, vasodilators
|
|
aneurysm
|
localized dilation or outpouching or an artery
|
|
major risk for aneurysm
|
atherosclerosis
|
|
aneurysm management
|
control BP w/antihypertensives to prevent rupture
|
|
Berry aneurysm
|
@ circle of willis
|
|
Dx aneurysm
|
CXR, ab. ultrasound, TEE, tomography, MRI, angiography
|
|
s/s of aortic dissection
|
ripping/tearing pain, pallor, sweating, tachycardia, diff. BP in each arm, LE paralysis, SHOCK
|
|
ways to prevent aneurysm rupture
|
bedrest, legs flat/avoid crossing, calm environment, avoid valsalva's (stool softeners, avoid reaching, lift team), antihypertensives, monitor EKG, vs, I/O
|
|
operable size for aneurysm
|
thoracic: >6cm
abdominal: >5cm |
|
surgical procedures for aneurysm
|
open procedure (graft), endovascular stent graft
|
|
postop aneurysm surgery complications
|
renal failure, graft occlusion, resp. distress, arrhythmia, paralytic ileus, sepsis
|
|
post aneurysm repair nursing actions
|
colloids, IV fluids, monitor vs, perfusion distal to graft, resp., NG tube, DVT prophylaxis, avoid valsalva's
|
|
venous disorders
|
venous occlusion, ineffective venous bloodflow (stasis, clotting, congestion)
|
|
risks for venous thrombosis
|
immobile, surgery, cancer, trauma, pregnancy, hormone therapy, coagulation disorder
|
|
DVT
|
dull aching pain in extremity, cyanosis, elevated temp., malaise
|
|
Dx thrombophlebitis
|
venogram, MRI, doppler
|
|
thrombophlebitis meds
|
anticoagulants, antiplatelets, thrombolytics, analgesics
|
|
thrombophlebitis nursing actions
|
pain relief, decrease edema, prevent ulceration (bed cradle), bedrest, no massage, monitor meds, hr, resp.
|
|
thrombophlebitis surgical interventions
|
venous thrombectomy, vena cava filter, ligation, plication
|
|
norm Na levels
|
135-148
|
|
norm K levels
|
3.4-5.3
|
|
norm BUN
|
3-29
|
|
norm WBCs
|
3.8-10.8
|